Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains

Citation data:

Virology, ISSN: 0042-6822, Vol: 315, Issue: 1, Page: 124-134

Publication Year:
2003
Usage 266
Downloads 230
Abstract Views 36
Captures 25
Readers 24
Exports-Saves 1
Citations 66
Citation Indexes 66
Repository URL:
http://digitalcommons.unl.edu/virologypub/216
DOI:
10.1016/s0042-6822(03)00521-x
Author(s):
Xiang, Shi-Hua; Wang, Liping; Abreu, Mariam; Huang, Chih-Chin; Kwong, Peter D.; Rosenberg, Eric; Robinson, James E.; Sodroski, Joseph
Publisher(s):
Elsevier BV
Tags:
Immunology and Microbiology; Human immunodeficiency virus (HIV-1); Primary HIV-1 isolates; CD4-induced (CD4i) antibodies; Neutralizing antibodies; Epitope mapping; Human monoclonal antibody E51; Structured treatment interruption (STI); Soluble CD4 (sCD4); Envelope glycoprotein (gp120); Virology
article description
Human immunodeficiency virus (HIV-1) enters target cells by binding its gp120 exterior envelope glycoprotein to CD4 and one of the chemokine receptors, CCR5 or CXCR4. CD4-induced (CD4i) antibodies bind gp120 more efficiently after CD4 binding and block the interaction with the chemokine receptor. Examples of CD4i antibodies are limited, and the prototypes of the CD4i antibodies exhibit only weak neutralizing activity against primary, clinical HIV-1 isolates. Here we report the identification of a novel antibody, E51, that exhibits CD4-induced binding to gp120 and neutralizes primary HIV-1 more efficiently than the prototypic CD4i antibodies. The E51 antibody blocks the interaction of gp120–CD4 complexes with CCR5 and binds to a highly conserved, basic gp120 element composed of the β19-strand and surrounding structures. Thus, on primary HIV-1 isolates, this gp120 region, which has been previously implicated in chemokine receptor binding, is accessible to a subset of CD4i antibodies.